Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-702 in Advanced or Metastatic NSCLC
NCT04667975Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2020
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CKD-702 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 1 more. Status: unknown.
02
Drugs
CKD-702
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04667975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667975.